Abbott Boosts Holdings in SpectRx
NORCROSS, Ga., Sept. 7 -- SpectRx said that Abbott Laboratories Inc. will buy an additional $1 million of its stock as part of a milestone payment, but it agreed to postpone payment of another $1 million. The milestone payments are part of an agreement to commercialize SpectRx's diabetes monitoring device. The SpectRx device is worn on top of the skin and measures glucose levels by using a laser to create microscopic holes, or micropores, and draw samples of interstitial fluid.
Norcross, Georgia-based SpectRx said the $1 million stock purchase will increase medical device maker Abbott's common stock ownership in SpectRx to about 5.9 percent. SpectRx said it expects payment of the remaining $1 million before the end of 2002. The second payment and a portion of the first payment are subject SpectRx maintaining its rights to sublicense to Abbott certain technologies it licensed from Altea Development Corp. SpectRx and Altea are currently in arbitration related to their license agreement.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024